# Filing Detail

Form 8-K - Current report:
SEC Accession No. 0000950170-25-003832
Filing Date
2025-01-10
Accepted
2025-01-10 08:36:20
Documents
28
Period of Report
2025-01-10
Items
Item 2.02: Results of Operations and Financial Condition
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | 8-K | fdmt-20250110.htm iXBRL | 8-K | 86948
2 | EX-99.1 | fdmt-ex99_1.htm | EX-99.1 | 19398
3 | GRAPHIC | fdmt-ex99_1s1.jpg | GRAPHIC | 178813
4 | GRAPHIC | fdmt-ex99_1s2.jpg | GRAPHIC | 482955
5 | GRAPHIC | fdmt-ex99_1s3.jpg | GRAPHIC | 483048
6 | GRAPHIC | fdmt-ex99_1s4.jpg | GRAPHIC | 388365
7 | GRAPHIC | fdmt-ex99_1s5.jpg | GRAPHIC | 471603
8 | GRAPHIC | fdmt-ex99_1s6.jpg | GRAPHIC | 305389
9 | GRAPHIC | fdmt-ex99_1s7.jpg | GRAPHIC | 343194
10 | GRAPHIC | fdmt-ex99_1s8.jpg | GRAPHIC | 229310
11 | GRAPHIC | fdmt-ex99_1s9.jpg | GRAPHIC | 416712
12 | GRAPHIC | fdmt-ex99_1s10.jpg | GRAPHIC | 305878
13 | GRAPHIC | fdmt-ex99_1s11.jpg | GRAPHIC | 385389
14 | GRAPHIC | fdmt-ex99_1s12.jpg | GRAPHIC | 302109
15 | GRAPHIC | fdmt-ex99_1s13.jpg | GRAPHIC | 390208
16 | GRAPHIC | fdmt-ex99_1s14.jpg | GRAPHIC | 483084
17 | GRAPHIC | fdmt-ex99_1s15.jpg | GRAPHIC | 157171
18 | GRAPHIC | fdmt-ex99_1s16.jpg | GRAPHIC | 472738
| Complete submission text file | 0000950170-25-003832.txt |  | 8214883

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
19 | XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT | fdmt-20250110.xsd | EX-101.SCH | 24937
30 | EXTRACTED XBRL INSTANCE DOCUMENT | fdmt-20250110_htm.xml | XML | 4712

Mailing Address 5858 HORTON STREET #455 EMERYVILLE CA 94608
Business Address 5858 HORTON STREET #455 EMERYVILLE CA 94608 5105052680
4D Molecular Therapeutics, Inc. (Filer) CIK: 0001650648 (see all company filings)

EIN.: 473506994 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39782 | Film No.: 25520608
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)